Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half af­ter be­com­ing the ex­per­i­men­tal treat­ment of choice for a new­ly di­ag­nosed pres­i­dent, Re­gen­eron’s an­ti­body cock­tail has re­ceived emer­gency use au­tho­riza­tion from the FDA. It will be used to treat non-hos­pi­tal­ized Covid-19 pa­tients who are at high-risk of pro­gress­ing.

Al­though the Rgen­eron drug is not the first an­ti­body treat­ment au­tho­rized by the FDA, the news comes as a sig­nif­i­cant mile­stone for a com­pa­ny and a treat­ment sci­en­tists have watched close­ly since the out­break be­gan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER